The Latest Breaking News from Gilead

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return.

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.